Global Epidemiology of Urticaria: Increasing Burden among Children, Females and Low-income Regions

Peck, Gabrielle M.; Hashim, M. Jawad; Shaughnessy, Cristin N.; Muddasani, Suraj; Elsayed, Nourhan Ali; Fleischer, Alan B.

doi:10.2340/00015555-3796

Cited by 27 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Risk factors reported for AU include high population density 15 and personal 32 and parental history of allergic diseases 2,33 . Higher prevalence and/or higher risk of having AU may be associated with poverty and lower socio-economic status 14,15 , whereas risk for CU was linked to high income and socio-economic status in some studies 2, 23,34 but not all 35,36 . In studies involving twins, genetic factors could partly explain susceptibility to urticaria 32 .…”

Section: Risk Factorsmentioning

confidence: 92%

“…However, each urticaria subtype has its own prevalence within different populations. The prevalence of AU is highest in children <5 years of age [14][15][16] , whereas CU, especially CSU, is most prevalent in women >30 years old 6, [17][18][19][20][21] . Adult patients with CSU are older than adult patients with CIndU (average age ~30-70 years versus ~20-40 years) and have older age of disease onset (~30-50 years versus ~20-35 years).…”

Section: Prevalence and Incidencementioning

confidence: 99%

“…For 2017, the prevalence of urticaria was estimated at 86 million cases and the annual incidence at 160 million cases globally 14 . However, each urticaria subtype has its own prevalence within different populations.…”

Section: Prevalence and Incidencementioning

confidence: 99%

“…No significant changes in the global prevalence, incidence and the years of life lived with disability were seen for urticaria between 1990 and 2017 (reF. 14 ). The consistent increase in CU prevalence in South Korea 21,24 , Italy 25,26 and Taiwan 27 may be linked to country-specific demographic, environmental and behavioural factors and changes.…”

Section: Prevalence and Incidencementioning

confidence: 99%

See 3 more Smart Citations

Urticaria

Kolkhir

Giménez‐Arnau

Kulthanan

et al. 2022

Nat Rev Dis Primers

180

View full text Add to dashboard Cite

show abstract

Section: Risk Factorsmentioning

confidence: 92%

Section: Prevalence and Incidencementioning

confidence: 99%

Section: Prevalence and Incidencementioning

confidence: 99%

Section: Prevalence and Incidencementioning

confidence: 99%

See 2 more Smart Citations

Urticaria

Kolkhir

Giménez‐Arnau

Kulthanan

et al. 2022

Nat Rev Dis Primers

180

View full text Add to dashboard Cite

show abstract

“…Chronic itch data were extracted from the University of Washington Institute for Health Metrics and Evaluation GBD database [10] . GBD is a public database providing global epidemiological data on 354 infections and diseases from 1990 to 2017 [11][12][13] . Data can be sorted by location, year, context, age, metric, measure, sex, and cause.…”

Section: Methodsmentioning

confidence: 99%

Global epidemiology of itch from 1990 to 2017: gender, age, sanitation, and air pollution as risk factors

Kulkarni

Liu

Aggarwal

et al. 2022

Itch

View full text Add to dashboard Cite

Background: Itch is a symptom with significant physical, psychological, and financial burden worldwide. Symptom-specific and demographic risk factors have been published although community-level risk factors have not been thoroughly studied. Objectives: To describe the epidemiological risk factors of itch and to present a hypothesis that can account for these trends. Materials and methods: Itch incidence, prevalence, and years lost to disability (YLD) by age, sex, world region, socio-demographic index, percent of population using basic sanitation services, mortality due to air pollution, and gross domestic product (GDP) per capita were obtained from the University of Washington Institute for Health Metrics and Evaluation Global Burden of Disease (GBD), World Health Organization Global Health Observatory (WHO GHO), and Worldometer databases. Linear regression models were utilized to analyze the relationship of sanitation, air pollution, and GDP with itch incidence, prevalence and YLD. Results: Female sex and age were positively associated with higher incidence of itch. The percent of population using basic sanitation services was also positively correlated with itch incidence, prevalence, and YLD (P<0.001). Mortality rate due to air pollution was negatively associated with itch incidence, prevalence, and YLD (P<0.001). However, GDP per capita was not associated with the incidence (P=0.5), prevalence (P=0.8), and YLD (P=0.7) of itch. Conclusions: The “hygiene hypothesis” might explain global trends of itch as more industrialized countries have higher itch incidence rates. Thus, approaches which target molecular pathways involved in the “hygiene hypothesis” may lead to a decreased global itch burden.

show abstract

Bioequivalence of 2 Pediatric Formulations of Fexofenadine Hydrochloride Oral Suspension

Rauch,

Lucio,

De Fer

et al. 2023

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

Fexofenadine hydrochloride (HCl) is a second‐generation, nonsedating, histamine H1‐receptor antagonist used to manage seasonal allergic rhinitis and chronic idiopathic urticaria. A new oral pediatric suspension of fexofenadine HCl has been developed, with the preservative potassium sorbate replacing parabens. The objective of this phase 1 single‐center, open‐label, randomized, 2‐treatment, full‐replicated, 4‐period, 2‐sequence crossover study in healthy adult volunteers was to assess the bioequivalence of 30 mg of the new oral suspension of fexofenadine HCl (test) versus 30 mg of the marketed pediatric oral suspension of fexofenadine HCl (reference). The replicate design was based on the high intra‐individual variability of fexofenadine (>30% on Cmax). The study comprised 68 randomized and treated volunteers. Plasma concentrations of fexofenadine were similar following the administration of a single dose of each formulation. Cmax, AUClast, AUC, median tmax, and mean t1/2z were similar between administrations of the same fexofenadine formulation and between formulations. A high intra‐individual variability was confirmed with both formulations. Bioequivalence of the test and reference fexofenadine HCl formulations was demonstrated as the 90% confidence intervals of the geometric least squares mean ratio for Cmax, AUClast, and AUC of fexofenadine were all within the bioequivalence range of 0.80‐1.25. There were no serious adverse events (AEs) or study discontinuations due to treatment‐emergent AEs with either fexofenadine HCl formulation. The new paraben‐free fexofenadine HCl 30‐mg oral suspension and marketed fexofenadine HCl 30‐mg pediatric oral suspension are bioequivalent under fasting conditions, with no safety concerns and a safety profile consistent with the known profile of fexofenadine.

show abstract

Global Epidemiology of Urticaria: Increasing Burden among Children, Females and Low-income Regions

Cited by 27 publications

References 28 publications

Urticaria

Urticaria

Global epidemiology of itch from 1990 to 2017: gender, age, sanitation, and air pollution as risk factors

Bioequivalence of 2 Pediatric Formulations of Fexofenadine Hydrochloride Oral Suspension

Contact Info

Product

Resources

About